Back to News
Market Impact: 0.55
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Definium Therapeutics reported positive top-line results from its second Phase III Panorama study of DT120 ODT 100 mcg for generalized anxiety disorder. The single-dose treatment met its primary endpoint and all key secondary endpoints, materially strengthening the clinical case for the drug and creating a potentially significant catalyst for DFTX shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
DFTX0.88
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- Berkshire-owned utility’s wildfire lawsuits head to Oregon Supreme Court
- McDonald's is about to report earnings. Here's what to expect